

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schwarz Pharma AG
Serial No.: 10/519,487
Filed: April 27, 2005
Title: Utilization of Heteroarene Carboxamide as Dopamine-d3 Ligands for the
Treatment of CNS Diseases
Group Art Unit: 1624
Examiner: E.B. Bernhardt
Confirmation No.: 6970
Docket No.: 6102-000109/US/NP

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMITTED ELECTRONICALLY VIA EFS-WEB

Sir:

**STATEMENT UNDER 37 CFR 3.73(b) AND REVOCATION OF
POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY
AND CHANGE OF CORRESPONDENCE ADDRESS**

1. STATEMENT UNDER 37 CFR 3.73(b):

Under 37 C.F.R. § 3.73(b), the undersigned hereby state:

SCHWARZ PHARMA AG, a Germany corporation, is the Assignee of the entire right, title and interest in the above-identified Application.

An assignment from the inventor(s) of the above identified Application was recorded in the United States Patent and Trademark Office at Reel 016173, Frame 0805.

The undersigned, whose titles are supplied below, are authorized to act on behalf of the Assignee.

2. POWER OF ATTORNEY

We hereby revoke all previous powers of attorney given in the above identified Application.


We hereby appoint each practitioner associated with the Customer Number 28997 of Harness, Dickey & Pierce, P.L.C., our attorneys with full power of substitution and revocation, to prosecute this Application and to transact all business in the Patent and Trademark Office connected therewith.

3. CHANGE OF CORRESPONDENCE ADDRESS

We request the Patent and Trademark Office to change the correspondence address for the above-identified application to the address associated with Customer No. 28997, Harness, Dickey & Pierce, P.L.C., 7700 Bonhomme, Suite 400, St. Louis, MO 63105.
Telephone: 314-726-7500, Email: tkeane@hdp.com.

For **SCHWARZ PHARMA AG**

Date: June 22, 2007



Name: Dr. S. Krohn

Title: Head of Patent Department

Date: June 22, 2007



Name: Dr. F. Dreßen

Title: Eur. Patent Attorney